89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investor Contact:SAN FRANCISCO, June 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 25,500 shares of the Company's common stock to two new employees (the "Inducement Grants") on June 10, 2024 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年6月14日，美國舊金山(GLOBE NEWSWIRE)--臨床階段的生物製藥公司89bio，Inc. (該"公司"或"89bio") (納斯達克:ETNB)，專注於開發和商業化治療肝臟和代謝性疾病的創新療法。今天，公司的董事會薪酬委員會批准授予非合格股票期權，以購買2名新僱員(該"誘因授予")25,500股公司普通股，授予日期爲2024年6月10日(該"授予日期")。該誘因授予是根據公司的2023年誘因計劃(該"計劃")授權的。該誘因授予是根據納斯達克規則5635(c)(4)授予的，旨在促使這些個人按照其與89bio的僱傭協議進入89bio。
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio's common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to each employee's continued employment with 89bio through the applicable vesting dates.
此次誘因授予的每股行權價格等於授予日89bio普通股的收盤價格，期權的行權期爲4年，其中行權期滿1週年時，公司普通股的25%將獲得行權，其餘普通股將在接下來的12個相等季度獲得行權，前提是員工能夠持續就職89bio 。
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
關於89bio 89bio是一家專注於爲患有肝臟和代謝性疾病的患者開發最佳療法的臨床階段生物製藥公司。該公司致力於通過臨床發展其領先候選藥物pegozafermin，用於治療代謝性功能障礙相關脂肪肝（MASH）和嚴重高三酰甘油血癥（SHTG）。Pegozafermin是一種經過特殊設計的、潛在的最佳成長因子21類似物（FGF21類似物），通過糖基PEG化技術優化生物活性，並具有延長半衰期的特點。公司總部位於舊金山。欲了解更多信息，請訪問www.89bio.com或關注該公司的
(“公司”)是一家臨床階段的生物製藥公司，致力於開發對肝臟和心血管代謝疾病患者來說最佳的治療方案。公司專注於通過使其主導候選藥物pegozafermin快速進入臨床開發，治療代謝紊亂相關脂肪肝（MASH）和嚴重高三酰甘油血癥（SHTG）。Pegozafermin是一種通過糖基PEG化技術，經過特殊設計的、潛在的最佳成長因子21類似物（FGF21類似物），其延長半衰期可優化生物活性。公司總部位於舊金山。欲了解更多信息，請訪問 www.89bio.com或關注該公司的 LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
投資者聯繫人：
Annie Chang
89bio公司
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
PJ Kelleher
LifeSci Advisors，LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
媒體聯繫人：
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com